| __timestamp | Iovance Biotherapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 49315000 |
| Thursday, January 1, 2015 | 12390000 | 75043000 |
| Friday, January 1, 2016 | 25602000 | 83749000 |
| Sunday, January 1, 2017 | 21262000 | 122682000 |
| Monday, January 1, 2018 | 28430000 | 207761000 |
| Tuesday, January 1, 2019 | 40849000 | 284812000 |
| Wednesday, January 1, 2020 | 60210000 | 317875000 |
| Friday, January 1, 2021 | 83664000 | 282660000 |
| Saturday, January 1, 2022 | 104097000 | 451421000 |
| Sunday, January 1, 2023 | 106916000 | 481871000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Iovance Biotherapeutics, Inc. and Sarepta Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Iovance's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion and investment in innovation. Meanwhile, Sarepta's expenses grew by approximately 880%, indicating a robust commitment to scaling operations and enhancing market presence. Notably, in 2023, Sarepta's SG&A expenses were nearly 4.5 times higher than Iovance's, underscoring its larger operational scale. These trends highlight the strategic financial maneuvers of these biotech leaders as they navigate the competitive landscape. As the industry evolves, monitoring such financial indicators will be key to understanding the future direction of these companies.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?